478 related articles for article (PubMed ID: 28571501)
1. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of the biosimilar CT-P13.
Yoo DH
J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
[TBL] [Abstract][Full Text] [Related]
4. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
5. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
7. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
8. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
Farkas K; Molnár T
Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
[TBL] [Abstract][Full Text] [Related]
9. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
12. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
BioDrugs; 2020 Feb; 34(1):89-98. PubMed ID: 31734899
[TBL] [Abstract][Full Text] [Related]
13. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
[TBL] [Abstract][Full Text] [Related]
14. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
15. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
16. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
[TBL] [Abstract][Full Text] [Related]
17. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview.
Song YJ; Nam SW; Suh CH; Choe JY; Yoo DH
Expert Opin Drug Metab Toxicol; 2023; 19(11):751-768. PubMed ID: 37842948
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
